Vancouver, British Columbia, December 15th, 2020 — Genix Pharmaceuticals Corporation (TSX-V: GENX) (“GENIX” or the “Company”) GENIX is pleased to announce the appointment of Danny Lee as Chief Financial Officer.
Mr. Lee will replace Jamie Lewin as CFO who will remain a director of the Company and will assist in the transition of this role to Mr. Lee. The Company would like to thank Mr. Lewin for his hard work in transitioning Genix to its current focus on the generic ophthalmic drug and nutraceutical space.
Mr. Lee is a Chartered Professional Accountant (CPA, CA) with more than 20 years of experience working with public companies in mineral exploration, software, technology and distribution. Mr. Lee’s experience includes financial reporting for both Canadian and US listed companies with international operations, corporate finance, strategic planning, tax planning, corporate governance, equity financings and due diligence for acquisitions. Mr. Lee has a Bachelor of Commerce degree from the University of British Columbia.
Mr. Sina Pirooz, CEO of the Company, states, “We are excited to have the opportunity to work with Danny as we continue to move the Company towards its goal of becoming a leader in the generic ophthalmic and nutraceuticals space. Additionally, I’d like to personally thank Mr. Lewin for his hard work on behalf of the Company and our shareholders.”
The Company has granted 400,000 stock options to certain officers at a price of $0.22 per share, with an expiry date of 5 years. The options are subject to TSX Venture Exchange approval pursuant to the Company’s stock options plan.
Genix Pharmaceuticals Corporation is an early stage life sciences company that is focused on acquisition and development of novel and innovative generic ophthalmic and nutraceutical products. We intend to sell these products through traditional retail outlets as well as direct to consumer and e-commerce platforms. Genix plans to market its products in Canada, the USA, Europe and Asia. Genix is committed to providing safe and effective, evidence-based ophthalmic drugs and over the counter products to consumers.
On behalf of the Board,
Sina Pirooz, CEO, Director
Genix Pharmaceuticals Corporation
For more information regarding GENIX, please contact:
Kevin Bottomley, Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.